ERAS Program in Thoracic Surgery Analyzed the Effects on the Rates of Complications, Readmission and Length of Stay

NCT04579601 COMPLETED

Lung cancer is the leading cause of cancer death worldwide, representing 20,55% and 14% of cancer deaths in Spain and the United States, respectively. Currently, pulmonary resection is the treatment of choice for lung cancer. However, this surgery is associated with significant complications in almost 50% of the cases, possibly delaying patient recovery and consequently increasing hospitalisation costs. Professor Henrik Kehlet described ERAS programs at the end of the last century. His ideas were that the application of specific measures based on scientific evidence during the perioperative period of the patient could decrease the stress produced by surgical aggression. Thus, in recent years, ERAS programs have proven effective in reducing surgical complications, length of stay and hospital costs. Over the last years, specific ERAS surgical approaches have been described for thoracic surgery. Nevertheless, there is still a lack of evidence to support ERAS programs for pulmonary resection surgery, particularly in terms of clinical results combined with minimally invasive procedures. Our study aims to analyze the effects of the implementation of an ERAS program in patients undergoing pulmonary resection in a tertiary university hospital on the rates of complications and readmission and the length of stay.

Details

Lead sponsor	Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Status	COMPLETED
Enrolment	50
Start date	Mon Jan 01 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Thoracic Surgery

Interventions

• ERAS program

Countries

Spain